IBI303 与阿达木单抗治疗中国强直性脊柱炎:随机双盲 III 期等效性试验
这项在中国 20 个中心开展的 III 期随机双盲等效性试验,将 438 例活动性强直性脊柱炎患者按 1:1 分配接受 IBI303 或阿达木单抗 40 mg 皮下注射每 2 周至第 22 周。
要点
- IBI303 与阿达木单抗在 ASAS20 应答上达到预设等效。
- 两组治疗中出现的不良事件发生率相似。
核心结论
- IBI303 与阿达木单抗在强直性脊柱炎治疗中显示疗效等效,疗效、安全性和免疫原性高度相似。
研究设计与样本
- III 期多中心双盲平行随机对照等效性试验,在中国 20 个中心开展。
- 438 例患者随机 1:1 接受 IBI303 40 mg 或阿达木单抗 40 mg 皮下注射每 2 周至第 22 周。
- 纳入 18 至 65 岁、符合 1984 年修改纽约标准、对 NSAIDs 治疗 4 周或以上无应答/应答不足/不耐受且疾病活动的强直性脊柱炎患者。
- 主要终点为治疗第 24 周达到 ASAS20 应答标准的患者比例,等效界值为组间差异 95%CI 在 -15% 至 15% 之间。
主要发现
- IBI303 组 220 例中 174 例(79%)和阿达木单抗组 218 例中 178 例(82%)发生治疗中出现的不良事件。
关键数值与推荐
- 等效界值为组间应答率差异的 95%CI 在 -15% 至 15% 之间。
临床怎么用
- IBI303 可作为中国强直性脊柱炎患者阿达木单抗的替代治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: China approved adalimumab for the treatment of ankylosing spondylitis in 2013. However, the cost of the standard dose regimen exceeds ¥15 000 (around US$2250) per month, which is well beyond affordability for most Chinese patients. No biosimilars of adalimumab are available in China; IBI303 is a monoclonal antibody against TNFα that is currently in development. This study aimed to assess the clinical equivalence of IBI303 to adalimumab in patients with ankylosing spondylitis. METHODS: This phase 3, multicenter, double-blind, parallel, randomised controlled equivalence trial was done in 20 centers across China. Patients were randomly assigned in a 1:1 ratio to receive either 40 mg of IBI303 or 40 mg of adalimumab as a subcutaneous injection every 2 weeks until week 22. Patients were eligible for inclusion if they were between 18 and 65 years old, fulfilled the 1984 Modified New York Criteria for ankylosing spondylitis, were non-responders, inadequate responders, or intolerant to treatment with NSAIDs for 4 or more weeks, and had active ankylosing spondylitis defined by two or more indicators of disease severity. The investigators, site staff, patients, sponsors, and the contract research organisation were masked to treatment allocation. The primary outcome was the proportion of patients who met the Assessment of SpondyloArthritis international Society (ASAS) Response Criteria for a 20% improvement (ASAS20) at week 24 after treatment. Equivalence was established if the 95% CI of the difference in responses between groups was between -15% and 15%. Efficacy analyses were done in the full analysis population and in the per-protocol population. Safety analyses were done in all randomly assigned patients who received at least one drug dose. This trial is registered with ClinicalTrials.gov, number NCT02893254. FINDINGS: Between Sept 22, 2016, and May 11, 2018, 438 patients were randomly allocated either to the biosimilar IBI303 group (n=220) or the adalimumab group (n=218). In the full analysis population, 165 (75%) of 220 patients in the IBI303 group (95% CI 68·7-80·6) and 158 (72%) of 218 patients in the adalimumab group (66·0-78·3) reached the primary outcome of ASAS20 at week 24. The difference between the two groups was 2·3% with a 95% CI of -5·9 to 10·6, which fell within the pre-specified equivalence boundaries at week 24 (-15 to 15). In the per-protocol population, 163 (80%) of 203 patients in the IBI303 group reached ASAS20 at week 24 (95% CI 74·1-85·5), compared with 150 (80%) of 188 patients in the adalimumab group (73·3-85·3%). The difference between the groups was 0·6% with a 95% CI of -7·4 to 8·6%, which also fell within the pre-specified equivalence boundaries at week 24. Safety and tolerability profiles were similar between the two groups; 174 (79%) of 220 patients in the IBI303 group and 178 (82%) of 218 patients in the adalimumab group had treatment-emergent adverse events. INTERPRETATION: This trial showed therapeutic equivalence of IBI303 and adalimumab in the treatment of ankylosing spondylitis. The efficacy, safety, and immunogenicity of both drugs are highly similar. IBI303 could be an alternative treatment option for patients with ankylosing spondylitis in China. FUNDING: Innovent Biologics, National Major Scientific and Technological Special Project for "Significant New Drugs Development".
引用
- Xu H, Li Z, Wu J, et al. IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial. Lancet Rheumatol. 2019. PMID: 38229357. doi:10.1016/S2665-9913(19)30013-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。